Medtronic’s Guardian Connect continuous glucose monitoring system was approved by the FDA for diabetes patients ages 14 to 75 after a clinical trial showed that it accurately alerted patients about 98.5% of hypoglycemic events. The device uses an advanced glucose sensor to alert patients of potentially low or high glucose events and enables caregivers to monitor blood glucose levels of users in real time.
About The Author
What heaven can be more real than to retain the spirit-world of childhood, tempered and balanced by knowledge and common sense.
March 16, 2018
March 19, 2018